retatrutide weight loss clinical trial results Retatrutide: A Multi-Receptor Approach to Management Retatrutide, Eli Lilly's next generation

Side effect management tools, from nausea tracking to proactive clinical outreach, can stop small frustrations from turning into abandonment

doi: 10.1016/j.tips.2022.11.001

The Canadian market currently offers several approved medications, with Retatrutide representing what may become available in the near future

Properties: The drug is a combination of two hypoglycemic drugs with complementary mechanisms of action, designed to improve glycemic control in patients with type 2 diabetes mellitus: sitagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a representative of the biguanide class